Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abbot, abstention, Actemra, Additionally, adhere, aid, alienate, ambulatory, amyloid, antagonist, Apotex, ASC, assembled, attached, AV, begun, benchmark, benchmarking, beta, Biovitrum, budget, cardiac, carefully, CD, CDARC, CDER, CDs, charter, children, COBRA, contemplated, conviction, cord, CRDAC, creation, database, DBH, dedicated, delegated, dental, deviate, disregard, dopamine, drafting, dramatically, driven, ECG, embezzlement, encapsulate, entirety, ethical, exceed, exemplary, exploratory, faith, fee, fell, felony, filled, fit, formulaic, fragment, frequency, frozen, gathering, grossly, harassment, HCL, hearing, hemodialytic, hydroxylase, imprecise, inaccurate, inconsistent, incremental, inducing, input, insubordination, intangible, Interestingly, introduce, IRS, ixekizumab, job, Kineret, Liaison, Likewise, Lyn, malignant, managerial, mapping, masitinib, median, Medicaid, Merck, messaging, Meyer, misappropriation, misconduct, misjudge, mono, motivate, negligent, neuroleptic, neutrazumab, NMS, NOL, noncompetition, nonpublic, nonsolicitation, norm, NortheraTM, overturn, owed, paper, pateclizumab, Patheon, payout, PDUFA, Pearl, people, pipeline, plaque, plc, polarization, polyneuropathy, PR, psroriatic, QRS, ramp, realign, receptor, recoupment, referenced, Registry, renal, reputation, responding, return, reward, SA, sacrifice, Sandoz, sarilumab, satisfactorily, secukinumab, shipment, Simponi, situated, solicited, soliciting, spinal, spouse, spring, staggered, Substituted, successor, summer, Swedish, tabalumab, TAGP, talent, talented, telephone, Teva, Therof, tock, tool, Topline, Trademark, transformation, triple, unexercised, unpaid, unrestricted, User, vacation, VAS, VI, violation, visual, whichever, wind, winding, writing
Removed:
absence, Academy, add, adenosine, Albany, Allergy, allocate, Alzheimer, amelioration, analgesic, applied, attributable, augment, authored, Axelrod, Baylor, Beth, Biaggioni, biology, biomedical, Boston, BS, Bulletin, calculation, California, Cambridge, Canadian, category, centre, chaired, Clinic, collateralization, complement, consortia, CORRONA, counterparty, covering, creating, DANA, default, Department, Detroit, devoted, diabetic, diagnostic, Diego, dispose, dozen, Dysautonomia, editor, editorial, Edward, Engalaticheff, Eon, Essential, Experimental, extensively, Federation, fellow, fellowship, FFELP, fixed, foundation, founder, founding, franchise, Freeman, Harrow, Harvard, hedge, Horacio, Houston, illiquid, improve, includingHypertension, Institute, interaction, internship, intolerance, investigating, Italo, Jason, Joel, journal, Kaufmann, Kavanaugh, Keystone, King, Kremer, Lee, LeWitt, Macdonald, Maryland, Mayo, MD, Michigan, Minnesota, Missouri, mitigate, modification, Mount, Muscle, Nashville, neural, neurochemical, neurodegenerative, neurology, Neuromuscular, Neuropharmacology, neurophysiology, Neuroscience, nitric, Offsetting, ophthalmologic, oxide, pathophysiology, perspective, Peter, Phillip, physiology, postural, Professor, Psychiatry, rational, Rebecca, recipient, recognizing, recording, regularity, renewal, renowned, requiring, residency, resigned, resumed, reviewer, Rochester, Roy, Saint, secured, shift, Sinai, Southwestern, specialist, specialty, Stanford, steering, Stein, Strand, symmetry, tachycardia, teaching, Temple, Tennessee, Toronto, trained, Transmission, Tremor, UCSD, unprecedented, unpublished, Vanderbilt, Vibeke, Wayne, Wellesley, yearly
Filing tables
Filing exhibits
- 10-K Annual report
- 10.3 2004 Stock Plan, As Amended
- 10.6 Employment Agreement
- 10.17 Manufacturing Services Agreement
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification by the Chief Executive Officer Pursuant to Section 240.13A-14
- 31.2 Certification by the Chief Financial Officer Pursuant to Section 240.13A-14
- 32.1 Certification by the Chief Executive Officer Pursuant to 18 U.s.c. 1350
- 32.2 Certification by the Chief Financial Officer Pursuant to 18 U.s.c. 1350
Related press release
CHTP similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-132330) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(2) | Registration Statement (Form S-3 No. 333-141964) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(3) | Registration Statement (Form S-3 No. 333-161236) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(4) | Registration Statement (Form S-3 No. 333-171628) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(5) | Registration Statement (Form S-3 No. 333-179183) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(6) | Registration Statement (Form S-8 No. 333-137782) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(7) | Registration Statement (Form S-8 No. 333-144061) of Chelsea Therapeutics International, Ltd. and Subsidiary, |
(8) | Registration Statement (Form S-8 No. 333-160256) of Chelsea Therapeutics International, Ltd. and Subsidiary, and |
(9) | Registration Statement (Form S-8 No. 333-171627) of Chelsea Therapeutics International, Ltd. and Subsidiary; |
of our reports dated March 7, 2012, with respect to the consolidated financial statements of Chelsea Therapeutics International, Ltd. and Subsidiary and the effectiveness of internal control over financial reporting of Chelsea Therapeutics International, Ltd. and Subsidiary included in this Annual Report (Form 10-K) of Chelsea Therapeutics International, Ltd. and Subsidiary for the year ended December 31, 2011.
/s/ ERNST & YOUNG LLP
Raleigh, North Carolina
March 7, 2012